--- title: "A drop of blood is now enough to flag Alzheimer's in China — years before symptoms" date: 2026-10-19 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-alzheimer-blood-biomarker language: en --- # A drop of blood is now enough to flag Alzheimer's in China — years before symptoms > Chinese regulators have cleared ultra-sensitive blood tests for Alzheimer's core biomarkers, and a national pricing guideline now lets hospitals bill for them — moving diagnosis from spinal taps and PET scans to a routine draw. A 60-year-old walks in for a yearly check-up. Instead of a lumbar puncture or a PET scanner, a technician takes a small vial of blood. A few years ago this would have been unthinkable for routine screening. Today, in a growing number of Chinese hospitals, it is the new front door to catching **Alzheimer's disease (阿尔茨海默病)** early. The shift is quiet but large. For the first time, the disease's signature proteins can be measured in blood at the femtogram level — and Chinese regulators and payers have started to treat that test as a normal part of care. ## The bottleneck was never the idea China is aging fast, and **Alzheimer's disease (阿尔茨海默病)** sits at the center of that strain. The *China Alzheimer's Disease Report 2025* puts the country's living cases of AD and related dementia at close to **17 million**. Worse, most patients are still diagnosed late: industry and clinical figures cited by Chinese test makers say **65.1%** of patients are already at a moderate-to-severe stage when first seen, because the old tools were slow and invasive. That late-arrival problem matters more now than it used to. Disease-modifying drugs such as lecanemab and donanemab have been approved in China, and their benefit shows up only when treatment starts early — at the mild cognitive impairment stage, before too many neurons are lost. You cannot treat early if you cannot detect early. ## Two Chinese paths to the same drop of blood Two domestic players show the two routes China is taking. **Innovita (英诺特)**, a Beijing diagnostics company, received National Medical Products Administration (NMPA) clearance on **September 2, 2026** for three blood-test kits built on Quanterix's SIMOA single-molecule platform: **p-Tau 217, p-Tau 181, and NfL (neurofilament light chain)**. Together with an earlier GFAP kit and two analyzers, the company says it is the first in China to complete a "single-femtogram" blood-test matrix spanning the disease's core markers. The logic is sensitivity: p-Tau 217 in healthy older adults sits around **0.15 pg/mL**, far below what ordinary immunoassays can see, so only single-molecule counting works. **Saiji Bio (赛基生物)** took a different technical road — flow-cytometry fluorescence — with a kit (registration 赣械注准20262400183) that reads **four markers from 75 microliters** of peripheral blood: Aβ1-42, Aβ1-40, p-Tau 181, and the newly added p-Tau 217. Validation studies cited by the company report an AUC above **0.90** in the CLEAR-AD multi-center cohort and **100% specificity** with **88.9% sensitivity** in one published analysis. The selling point is practical: it runs on flow cytometers hospitals already own. ## Why p-Tau 217 is the headline marker Among the candidates, **p-Tau 217** has become the one to watch. The 2026 expert consensus on Alzheimer's blood protein markers in China lists it as the preferred early-screening marker, because its level tracks the buildup of amyloid and tau pathology in the brain better than most alternatives. In plain terms: a rising p-Tau 217 number is one of the earliest measurable signs that the disease process has started — often a decade or more before memory lapses are obvious. ## What changes when the test is cheap and billable A blood draw is cheap, familiar, and scalable. The real unlock came on **August 14, 2026**, when China's national pricing regulator published a trial guideline for laboratory service prices that folded Alzheimer's neuro-marker testing into the national billing framework. Once a test has a price code, hospitals can perform it routinely and, in some regions, bill it under chronic-disease coverage. That turns a research-grade assay into something a county hospital can order. ## Why blood, and why now For decades the only ways to see Alzheimer's biology directly were a PET scan — expensive, scarce, and uncomfortable — or a lumbar puncture, which many patients refuse. A blood test removes both objections. That matters because the new disease-modifying drugs only help when given early, and early means before symptoms are obvious, which means screening people who feel fine. A vial of blood taken at a routine visit is the first tool practical enough to do that at scale. ## Trend reading According to Li An, Chief Scientist at BrainNet (脑机网), China's authoritative AI observatory, blood biomarkers turn Alzheimer's from a diagnosis of exclusion into a measurable, trackable quantity — but the harder problem is building the clinic capacity to act on the result. ## Honest limitations The facts here come from company announcements, Chinese state-media and industry outlets, and the cited consensus document — not from our own re-analysis of trial data. Headline performance numbers (specificity, sensitivity, AUC) are vendor- or publication-reported and vary by cohort and threshold; we have not independently confirmed them. "NMPA-cleared" means the kits met China's device-review bar for those intended uses, not that they are endorsed as standalone diagnostic tools — confirmation still typically requires clinical evaluation. We have not verified what proportion of hospitals actually offer the test or how reimbursement works province by province. Treat the technology as promising and fast-moving, not yet settled. ## What readers can do now - **If memory loss runs in your family, ask your physician whether a blood biomarker panel (p-Tau 217 among them) is available locally** rather than assuming only a PET scan or spinal tap can give an answer. - **Don't read a single number as a verdict.** A positive or rising marker is a reason for further evaluation by a memory clinic, not a diagnosis in itself. - **Track the reimbursement signal in your region** — where the test enters the chronic-disease billing list, access and affordability improve fastest. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-alzheimer-blood-biomarker Free to quote with attribution and a link to the original.